Sangamo/Pfizer Data Competitive, But BioMarin (BMRN) is 'Meaningfully Ahead in Development' - Baird
April 2, 2019 12:45 PM
Baird analyst Michael Ulz reiterated an Outperform rating and $120.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) following competitive ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
